

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 950)

VOLUNTARY ANNOUNCEMENT – NATULAN OBTAINS DRUG REGISTRATION CERTIFICATE

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**” or “**Lee’s Pharm**”, together with its subsidiaries as the “**Group**”) on a voluntary basis.

The Board of the Company is pleased to announce that, on 19 April 2022, the Drug Registration Certificate for Natulan® (Procarbazine Hydrochloride Capsules) has been obtained from the China National Medical Products Administration (“**NMPA**”). Natulan® has been approved for combining with chemotherapy to treat Hodgkin’s lymphoma (“**HL**”) in adult.

The approval is based on the result from an open label, randomised, controlled, multicentre clinical study in China in which the safety and objective response rate (“**ORR**”) of baseline BEACOPP (chemotherapy combination that includes bleomycin, etoposide, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine and prednisone) and ABVD (chemotherapy combination that includes doxorubicin hydrochloride (Adriamycin), bleomycin, vinblastine and dacarbazine) regimens for patients with advanced HL was compared. A total of 93 advanced HL patients were enrolled and the study not only met the primary endpoint showing non-inferior ORR in baseline BEACOPP group compared with ABVD group, but also achieved significantly higher complete remission rate 16.22% (6/37) in baseline BEACOPP group (21 days per cycle) after 4 cycles of treatment vs 2.17% (1/46) in ABVD group (28 days per cycle).

The Group signed a distribution agreement with Leadiant Biosciences in May 2018, to exclusively commercialise Natulan® for Greater China.

* For identification purpose only

ABOUT NATULAN®

Natulán® (Procarbazine Hydrochloride Capsules) in combination chemotherapy is suitable for the treatment of HL and certain brain cancers (such as glioblastoma multiforme). It is a member of a group of medicines called alkylating agents. It was originally developed by Hoffmann-La Roche, which first filed a patent claiming its preparation process and its use.

ABOUT LEE'S PHARM

Lee's Pharm is a research-driven and market-oriented biopharmaceutical company with more than 25 years of operation in the pharmaceutical industry in China. The Company is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing based in Mainland China with global perspectives. The Company has established extensive partnerships with over 20 international companies and currently markets over 25 proprietary, generic and licensed-in pharmaceutical products in Mainland China, Hong Kong, Macau and Taiwan. The Company focuses on several key disease areas such as cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology and obstetrics, and has more than 40 products under different development stages stemming from both internal research and development as well as from the licensing and development, commercialisation, and manufacturing rights from various United States, European and Japanese companies. More information available at www.leespharm.com.

ABOUT LEADIANT BIOSCIENCES

Leadiant Biosciences is a research based global pharmaceutical company dedicated to the development, registration and commercialisation of novel and effective therapies that address the needs and improve the quality of life of patients suffering from rare and ultra-rare disease. Leadiant Biosciences operates as Leadiant Biosciences, Ltd. in the UK, acting as a distribution network in Europe and the rest of the world. More information available at www.leadiantbiosciences.com.

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 19 May 2022

As at the date of this announcement, Ms. Lee Siu Fong (Chairman) and Ms. Leelalertsuphakun Wanee are executive directors of the Company, Dr. Li Xiaoyi and Mr. James Charles Gale are non-executive directors of the Company, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive directors of the Company.